Alector, Inc. (ALEC) NASDAQ

2.84

-0.17(-5.65%)

Updated at September 08 09:43AM

Currency In USD

Alector, Inc.

Address

131 Oyster Point Boulevard

South San Francisco, CA 94080

United States of America

Phone

415 231 5660

Sector

Healthcare

Industry

Biotechnology

Employees

175

First IPO Date

February 07, 2019

Key Executives

NameTitlePayYear Born
Dr. Arnon Rosenthal Ph.D.Co-Founder, Chief Executive Officer & Director888,5661956
Dr. Marc Grasso M.D.Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer703,2491974
Dr. Saraswati Kenkare-Mitra Ph.D.President and Head of Research & Development1.18M1968
Ms. Danielle Pasqualone J.D., Ph.D.General Counsel0N/A
Ms. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer0N/A
Ms. Katie HoganSenior Director of Corporate Communication & Investor Relations0N/A
Mr. Giacomo Salvadore M.D.Chief Medical Officer0N/A
Ms. Clare Hunt M.B.A.Chief People Officer0N/A
Ms. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of Strategy0N/A
Mr. Neil Berkley M.B.A., M.S.Chief Business Officer01974

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.